|Bid||24.37 x 900|
|Ask||24.50 x 900|
|Day's Range||24.43 - 25.14|
|52 Week Range||14.33 - 28.81|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
How do we determine whether Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]